ENDONOVO THERAPEUTICS, INC.
ENDONOVO THERAPEUTICS, INC. (ENDV): 2 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.04 · 324% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for ENDONOVO THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$181K
Cash
$0
Quarterly Burn
$65K
Runway
—
Revenue
$2K
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| electroceuticals therapeutic devices | Preclinical |
| sofpulse | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Dec 2025Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| family cfo inc | 60 | $0 |
Frequently asked questions
How many drug candidates are in ENDONOVO THERAPEUTICS, INC.'s pipeline?
ENDONOVO THERAPEUTICS, INC. (ENDV) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ENDONOVO THERAPEUTICS, INC.'s lead drug candidate?
ENDONOVO THERAPEUTICS, INC.'s most advanced tracked candidate is electroceuticals therapeutic devices (Preclinical) for chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.
What is ENDONOVO THERAPEUTICS, INC.'s market capitalization?
ENDONOVO THERAPEUTICS, INC.'s market capitalization is approximately $181K.
Who is the CEO of ENDONOVO THERAPEUTICS, INC.?
Mr. Alan Brian Collier is the chief executive officer of ENDONOVO THERAPEUTICS, INC. (ENDV).
Get the full picture on ENDONOVO THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.